CNS-expression-pattern research on GLP-1R, GIPR, and GCGR is refining the mechanism map and suggesting that the therapeutic effects of incretin agonists may be more CNS-driven than the early pancreatic-focused pharmacology suggested
Receptor focus and regulatory status make them different tools
To our knowledge, our study is the first associating semaglutide treatment with transcriptomic signatures relating to alterations of the circadian rhythm
Paola Fioretto assessed the role of GLP-1RAs in the CKD and T2D nexus
The PlexusDx Precision Peptide Genetic Test analyzes 14 metabolic pathways and variants affecting dopamine, serotonin, and GLP1R sensitivity
Tirzepatide alone rarely causes dangerously low blood sugar, but combined with insulin or sulfonylureas, the risk increases